EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer

Xinrui Yang, Ke Zhang, Lijie Xia, Jinyao Li

iMetaMed · 2026-03 · 2 (1)

DOI: 10.1002/imm3.70030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift iMetaMed, online erschienen am 06.02.2026. Verfasst von Xinrui Yang und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 377 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pathogenesis of colorectal cancer (CRC) is closely associated with gut microbial metabolites, which exert crucial regulatory effects within the tumor immune microenvironment. These metabolites play a dual role in CRC immunity: certain metabolites promote tumor progression by inducing chronic inflammation, recruiting myeloid‐derived suppressor cells, and suppressing CD8 + T cell function; while others, such as short‐chain fatty acids and tryptophan metabolites, enhance anti‐tumor immunity and improve the efficacy of immune checkpoint inhibitors (ICBs). This paper systematically explores intervention strategies targeting this mechanism, including probiotics, prebiotics, metabolite adjuvants, and their combination with immunotherapy to overcome ICB resistance. Furthermore, the analysis of specific metabolites (e.g., cholic acid derivatives) and microbial signatures (e.g., enrichment of F. nucleatum ) has been identified as a potential avenue for the development of novel non‐invasive biomarkers, which could facilitate early screening and differential diagnosis. Notwithstanding the challenges encountered in the clinical translation of these technologies, the integration of multi‐omics and artificial intelligence with the immunoregulatory mechanisms and diagnostic potential of metabolites holds great promise for advancing precision medicine in the comprehensive management of CRC.

Zitieren

APA

Yang, X., Zhang, K., Xia, L., & Li, J. (2026). Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer. iMetaMed, 2(1). https://doi.org/10.1002/imm3.70030

Vancouver

Yang X, Zhang K, Xia L, Li J. Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer. iMetaMed. 2026;2(1). doi:10.1002/imm3.70030

BibTeX
@article{Yang2026,
  author = {Yang, Xinrui and Zhang, Ke and Xia, Lijie and Li, Jinyao},
  title = {Targeting Microbiome Metabolites: Reshaping Immunotherapy and Clinical Management Strategies for Colorectal Cancer},
  journal = {iMetaMed},
  year = {2026},
  volume = {2},
  number = {1},
  doi = {10.1002/imm3.70030}
}
Kostenlos starten →